Retension Pharmaceuticals, Inc. (Nasdaq: RTSN) reported financial results for the third quarter ended September 30, 2026, and announced the completion of an upsized initial public offering (IPO) in October 2026. The company, which focuses on developing treatments for hypertension, stated that the IPO generated gross proceeds of $51.75 million.

The IPO involved the sale of 4,312,500 shares of common stock at a price of $12.00 per share. This price included the full exercise of the underwriters' option to purchase 562,500 additional shares. Following the offering, the company’s common stock began trading on the Nasdaq Capital Market under the ticker symbol “RTSN” on October 9, 2026.

Regarding its clinical pipeline, Retension is currently conducting a randomized, placebo-controlled, dose-ranging Phase 2b trial of its lead candidate, RTN-001. The trial is evaluating the drug in approximately 280 patients with uncontrolled hypertension. The study’s primary endpoint is the change from baseline in office-seated systolic blood pressure at Week 4 versus placebo. The company anticipates releasing topline data from this trial in the first half of 2027.

On a financial basis, Retension reported a net loss of $5.9 million for the third quarter of 2026. Research and development expenses totaled $5.0 million for the quarter, compared to $1.4 million in the prior year period, largely due to costs associated with the Phase 2b trial. General and administrative expenses were $1.0 million for the quarter, up from $0.3 million in the prior year, driven by higher personnel costs.

As of September 30, 2026, the company reported cash and cash equivalents of $9.2 million. The filing notes that these figures do not include the net proceeds from the IPO, which closed after the quarter-end. Including the net proceeds of approximately $45.1 million from the offering, the company’s pro forma cash and cash equivalents as of September 30, 2026, were approximately $54.3 million.

In addition to the IPO, Retension highlighted recent leadership changes. The company added several executives with backgrounds in cardiovascular and biopharmaceutical development, including Alison D. Schecter as Chief Medical Officer, Alex Schwartz as Chief Financial Officer, and LeAnne Bloedon as Executive Vice President of Clinical Development and Operations. The company also formed a Scientific Advisory Board comprising leading investigators in hypertension and cardiology.